Johnson & Johnson to Stop Sales of LINX Reflux Management System Outside the U.S.

Johnson & Johnson announced it will discontinue sales of its LINX Reflux Management System, a device used to treat chronic acid reflux, in countries outside the United States by the end of March 2026. The decision, outlined in a letter to healthcare providers on September 17, was framed as a commercial decision rather than an issue of safety or effectiveness. For many patients, especially those who have undergone lung transplants, this could mean losing a crucial tool for symptom relief.

The LINX Reflux Management System: An Overview

The LINX Reflux Management System treats severe acid reflux using a small ring of magnetic beads implanted around the lower esophageal sphincter. This setup is effective at preventing stomach contents from flowing back up into the esophagus, which can cause discomfort and serious complications. Based on various clinical studies, approximately 85% of patients report significant improvement in their GERD symptoms after the procedure, making LINX a notable advancement and a less invasive alternative to traditional surgery.

Despite the positive outcomes, the decision to stop sales outside the U.S. could undo years of progress in treatment access for GERD patients. Surgeons are worried this shift will set back treatment options significantly, potentially leaving patients to rely on older, less effective therapies.

Concerns and Controversies Surrounding LINX

While the LINX device has shown many benefits, it is not without its issues. Back in 2018, J&J issued a recall due to concerns about the beads separating from the device. The company faced legal challenges in the U.S. arising from these issues. Some patients have reported complications that include difficulty swallowing, and a small percentage (around 5%) have experienced device removal due to erosion into the esophagus. These complications have naturally led to skepticism about the device’s long-term safety.

READ MORE